The evolution of mendelian randomization for investigating drug effects.

Thumbnail
View / Open Files
Authors
  Gill, Dipender
  Burgess, Stephen
Publication Date
2022-02-03
Journal Title
PLoS medicine
ISSN
1549-1277
Volume
19
Issue
2
Language
eng
Type
Article
This Version
VoR
Metadata
Show full item record
Citation
Gill, D., & Burgess, S. (2022). The evolution of mendelian randomization for investigating drug effects.. PLoS medicine, 19 (2) https://doi.org/10.1371/journal.pmed.1003898
Abstract
Dipender Gill and Stephen Burgess discuss the accompanying study by James Yarmolinsky and colleagues investigating the associations between genetically-proxied inhibition of antihypertensive drug targets and risk of common cancer subtypes using Mendelian randomization.
Keywords
Humans, Colorectal Neoplasms, Antihypertensive Agents, Angiotensin-Converting Enzyme Inhibitors, Risk Factors, Blood Pressure, Genetic Variation, Genome-Wide Association Study, Mendelian Randomization Analysis
Identifiers
PMC8812877, 35113864
External DOI: https://doi.org/10.1371/journal.pmed.1003898
This record's URL: https://www.repository.cam.ac.uk/handle/1810/334718
Rights
Attribution 4.0 International
Licence URL: https://creativecommons.org/licenses/by/4.0/
Statistics



Total file downloads (since January 2020). For more information on metrics see the IRUS guide.

Attribution 4.0 International
Except where otherwise noted, this item's licence is described as Attribution 4.0 International